Needham Maintains Buy on NeoGenomics, Lowers Price Target to $16

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $19 to $16.

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $19 to $16.

Total
0
Shares
Related Posts